Hosting "S venture Lab."
Strike Inc. will host the 54th "S venture Lab." open innovation event.
S venture Lab. serves as a platform embodying Strike's philosophy of "Building a community to change the world."
It is implemented with the aim of creating new collaborations between startups and established companies.
This time, Manabu Oura, CEO of FUNDINNO Inc., which went public in December 2025, will take the stage.
He will explain "behind-the-scenes insights of the IPO" and "next-generation funding strategies" – topics only possible to discuss now that the company is publicly listed.
In addition to the talk session, the event will feature pitches by notable startups and a networking session.
We invite all interested parties to join us—business companies and startups exploring business partnerships, VC/CVC representatives, and anyone with an interest in open innovation.
Event Summary
- Event Name
-
S Venture Lab.
- Date(s) (e.g. for exhibition)
-
Thursday, March 5, 6:30 PM to 8:30 PM
- organizing
-
S venture Lab. (Strike Inc.)
- Form (something takes)
-
hybrid
- Venue
-
SAKURA DEEPTECH SHIBUYA
(1-2 Sakuragaoka-cho, Shibuya-ku, Shibuya Sakura Stage Central Building 12F) - Entrance fee
-
free
- Language
-
Japanese
- How to apply
-
Advance registration is required. Please apply to participate using the form below.
https://www.sventurelab.com/event26_0305/
speaker
-
FUNDINNO, Inc. Representative Director and COOManabu Oura (Speaker) -
ABAKAM Co., Ltd. Representative DirectorNaoto Matsumoto (Moderator)
Featured Startups
-
Ultra-High Purity Co., Ltd. President and CEOMotohiro YokoyamaIndustry-academia collaboration develops method to directly enhance hydrogen purity beyond 6N level.
Previously, expensive palladium alloys were used,
but this technology employs more affordable vanadium alloys for new development.
High-purity hydrogen is essential for sub-2nm fine processing in semiconductor front-end processes.
A prototype generator has already achieved trial sales results.
Confirmation work for adoption is currently underway with Nippon Sanso HD Group, the industry leader. -
OrganTech Inc. Director and CTOMihō OgawaOrganTech is a research and development-focused biotech company aiming to bring next-generation medical care to society, based on its proprietary organ regeneration technology—the world's first of its kind.
Licensing of its flagship technology, "Tension-Added Three-Dimensional Artificial Skin," has already been completed for corporate use.
The next-generation dental device "Biohybrid Tooth" is currently undergoing specific clinical studies involving human subjects.
Preparations are underway for submission to the U.S. FDA (Food and Drug Administration).
Furthermore, in the field of hair regeneration, the technology has progressed to the safety confirmation stage, with multiple R&D pipelines reaching the final stages before commercialization and market launch.